Physician profile
Caitlin E Krouse
NPI 1184986259
$2,997.11
in general payments reported to CMS, 2019-2025
21 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $87.03 · 2024: $766 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.62 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $398.26 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $395.81 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $351.21 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $302.94 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $251.14 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $244.52 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.73 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $130.11 | 2023-2025 | Trintellix |
| Tris Pharma INC | $104.19 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $93.70 | 2024-2025 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.21 | 2025 | |
| Axsome Therapeutics, INC. | $87.75 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $83.95 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $82.43 | 2024 | |
| Supernus Pharmaceuticals, INC. | $53.41 | 2025 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $38.76 | 2023-2024 | Perseris, Sublocade |
| Biogen, INC. | $27.32 | 2025 | Zurzuvae |
| Brainsway USA INC | $22.11 | 2025 | Deep Tms System |
| Collegium Pharmaceutical, INC. | $21.33 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
| Noven Therapeutics, LLC | $14.03 | 2025 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Krouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.